Literature DB >> 1527428

The longevity of the immune response to filamentous hemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community.

T Tomoda1, H Ogura, T Kurashige.   

Abstract

Titers of antibodies to the filamentous hemagglutinin (FHA) and pertussis toxin (PT) of Bordetella pertussis were studied in patients from a semiclosed community after an outbreak of the disease in 1985 and in the general population. In convalescent-phase serum obtained after B. pertussis infection in patients in the semiclosed community, high anti-FHA IgG and anti-PT IgG titers were observed; these titers tended to disappear over the next 5 years. On the other hand, among the medical staff, high anti-FHA and anti-PT IgG titers persisted during the same 5-year period. It seems likely that anti-FHA and anti-PT IgG levels reflect the frequency of exposure to the bacteria and that B. pertussis is widespread in the Japanese population. Although the anti-FHA IgG antibody response decreased in patients from the semiclosed community, the cellular immune response was maintained.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527428     DOI: 10.1093/infdis/166.4.908

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.

Authors:  S Esposito; T Agliardi; A Giammanco; G Faldella; A Cascio; S Bosis; O Friscia; M Clerici; N Principi
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  The return of the 100-day cough: resurgence of pertussis in the 1990s.

Authors:  T W Tam; A Bentsi-Enchill
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

Review 3.  Laboratory diagnosis of pertussis: state of the art in 1997.

Authors:  F M Müller; J E Hoppe; C H Wirsing von König
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.